Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 2
2006 2
2007 1
2009 2
2010 4
2011 5
2012 10
2013 9
2014 26
2015 43
2016 69
2017 91
2018 93
2019 87
2020 110
2021 106
2022 93
2023 76
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

757 results

Results by year

Filters applied: . Clear all
Page 1
Obeticholic Acid.
[No authors listed] [No authors listed] 2019 Dec 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Dec 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644113 Free Books & Documents. Review.
Obeticholic acid (OCA) is a synthetically modified bile acid and potent agonist of the farnesoid X nuclear receptor (FXR) that is used to treat liver diseases including primary biliary cholangitis. Obeticholic acid has not been linked to elevations in …
Obeticholic acid (OCA) is a synthetically modified bile acid and potent agonist of the farnesoid X nuclear receptor (FXR) that …
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Younossi ZM, et al. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813633 Free article. Clinical Trial.
The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0.045), and 71 (23%) in the obeticholic acid 25 mg group (p=0.0002). The NASH resolution endpoint was not met (25 …
The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 …
Obeticholic Acid for Primary Biliary Cholangitis.
Floreani A, Gabbia D, De Martin S. Floreani A, et al. Biomedicines. 2022 Oct 2;10(10):2464. doi: 10.3390/biomedicines10102464. Biomedicines. 2022. PMID: 36289726 Free PMC article. Review.
However, 30-40% of patients unfortunately do not respond to this first-line therapy. Obeticholic acid (OCA) is the only registered agent for second-line treatment in UDCA-non responders. ...
However, 30-40% of patients unfortunately do not respond to this first-line therapy. Obeticholic acid (OCA) is the only regist …
Obeticholic Acid.
Krupa K, Hapshy V, Nguyen H, Parmar M. Krupa K, et al. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 33620812 Free Books & Documents.
Obeticholic acid is a medication used to manage and treat primary biliary cholangitis. This activity describes the indications, action, and contraindications for obeticholic acid as a valuable agent in managing primary biliary cholangitis. ...
Obeticholic acid is a medication used to manage and treat primary biliary cholangitis. This activity describes the indications …
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis.
Zhou J, Huang N, Guo Y, Cui S, Ge C, He Q, Pan X, Wang G, Wang H, Hao H. Zhou J, et al. Acta Pharm Sin B. 2019 May;9(3):526-536. doi: 10.1016/j.apsb.2018.11.004. Epub 2018 Nov 27. Acta Pharm Sin B. 2019. PMID: 31193776 Free PMC article.
Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in the therapy of liver fibrosis. ...
Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in the therapy of liver fibrosis. ...
Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW, Lynch KD. Chapman RW, et al. Br Med Bull. 2020 May 15;133(1):95-104. doi: 10.1093/bmb/ldaa006. Br Med Bull. 2020. PMID: 32282030 Review.
INTRODUCTION: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth …
INTRODUCTION: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist …
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. Nevens F, et al. N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840. N Engl J Med. 2016. PMID: 27532829 Free article. Clinical Trial.
METHODS: In this 12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10 mg (the 10-mg …
METHODS: In this 12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response …
Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice.
Zhuge A, Li S, Yuan Y, Han S, Xia J, Wang Q, Wang S, Lou P, Li B, Li L. Zhuge A, et al. Redox Biol. 2023 Feb;59:102582. doi: 10.1016/j.redox.2022.102582. Epub 2022 Dec 22. Redox Biol. 2023. PMID: 36584600 Free PMC article.
Obeticholic acid (OCA) has been examined to treat non-alcoholic steatohepatitis (NASH), but has unsatisfactory antifibrotic effect and deficient responsive rate in recent phase III clinical trial. ...
Obeticholic acid (OCA) has been examined to treat non-alcoholic steatohepatitis (NASH), but has unsatisfactory antifibrotic ef …
Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X, Ren Y, Cui Y, Li R, Wang C, Zhang Y. Xiong X, et al. Biomed Pharmacother. 2017 Dec;96:1292-1298. doi: 10.1016/j.biopha.2017.11.083. Epub 2017 Nov 22. Biomed Pharmacother. 2017. PMID: 29174575
The farnesoid X receptor (FXR) plays an important role in regulating bile acid homeostasis. Whether FXR activation by its agonist obeticholic acid (OCA) is contributed to improve sepsis-induced liver injury remains unknown. ...
The farnesoid X receptor (FXR) plays an important role in regulating bile acid homeostasis. Whether FXR activation by its agonist obetich …
757 results